Trials / Sponsors / Goldfinch Bio, Inc.
Goldfinch Bio, Inc.
Industry · 5 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases Kidney Diseases, Glomerulosclerosis, Focal Segmental Nephrosis | Phase 2 | 2021-07-27 |
| Completed | First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Dia Kidney Diseases, Diabetic Nephropathies, Diabetes Complications | Phase 1 | 2021-05-05 |
| Terminated | A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental | Phase 2 | 2020-07-28 |
| Terminated | A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies | — | 2019-12-20 |
| Completed | FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects Healthy Volunteers | Phase 1 | 2019-05-29 |